Background: Early diagnosis and effective treatment in systemic lupus erythematosus (SLE) has very crucial role. Anti dsDNA is very important diagnostic tool and activity marker in SLE. This study aimed to determine the association of anti dsDNA antibodies titer with non-renal manifestations of systemic lupus erythematosus and systemic lupus erythematosus disease activity index (SLEDAI). Patients and methods: It was a cross-sectional study and was carried out at Department of Rheumatology and Immunology, Tertiary Care Hospital, Lahore from Feb 2021 to May 2021. The study involved 69 male and female patients satisfying the systemic lupus international collaborating clinics (SLICC) classification criteria. Questions regarding different symptoms were asked and disease activity parameters were noted excluding renal parameters. Anti-dsDNA titers were measured from standard laboratory using immunofluorescence technique and were correlated with SLEDAI score. A written informed consent was obtained from every patient. Results: The mean age of the patients was 30.7±10.2 years while the mean duration of disease 1.94±2.65 years. We observed a female predominance among these patients with male to female ratio of 1:7.6. There were fifty-four (78.3%) patients with active disease. The mean anti-dsDNA levels were significantly higher in patients with active disease (315.73±481.68 vs. 78.46±113.64 IU/mL; p-value=0.003). There was a significantly strong positive correlation between anti-dsDNA levels and SLEDAI score (r=0.358; p-value=0.006). When compared, significant difference was observed in mean anti-dsDNA titers in patients with chronic cutaneous manifestations (p-value=0.040), lymphopenia (p-value= 0.012), pleurisy/pericarditis (p-value= 0.024) and leukopenia <3000/mm3 (p-value= 0.001). Conclusion: Anti-dsDNA antibodies titers are remarkably increased in patients with non-renal manifestations of systemic lupus erythematosus particularly with chronic cutaneous manifestations and leukopenia and positively correlate with disease activity status and SLEDAI score.
Objective: To compare the recurrence rate of breast carcinoma between modified radical mastectomy and breast conservative surgery in patients of breast cancer. Material and methods: This randomized controlled was conducted at Department of Surgery, Akhtar Saeed Medical and Dental College Lahore from September 2020 to June 2021. Total 70 females with breast cancer from last 3 years (any stage), age between 30-60 years with ASA grade I, II and III were selected. In group A MRM was performed while in group B, conservative surgery was performed. Recurrence of breast cancer between the both groups was compared. Results: Mean age of patients was 44.47 ± 9.41 years with age range 30-60 years. Mean age of patients of study group A and B was 43.57 ± 9.89 years and 45.37 ± 8.95 years respectively. In study group A (MRM group), recurrence of breast cancer was found in 6 (17.14%) patients while in study group B (Conservative surgery group), recurrence of breast cancer was noted in 15 (42.86%) patients. Difference of recurrence of breast cancer between the both groups was significant with p value 0.019. Conclusion: Findings of this study showed higher frequency of recurrence of breast cancer in cases managed with conservative surgery as compared to MRM. Most of the cases belonged to 3rd decade of life. Among non-obese cases, significant difference of recurrence was seen. Most of the cancer cases were multiparas but difference of recurrence was not significant. Higher number of married cases were reported with breast cancer and difference between conservative surgery group and MRM group was significant. Keywords: Breast cancer, recurrence, MRM, conservative surgery
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.